Hara, Kazuo
Hirase, Tetsuaki
Pathadka, Swathi http://orcid.org/0000-0002-1793-1800
Cai, Zhihong
Sato, Manaka
Ishida, Noriyuki
Takemura, Ryo
Funding for this research was provided by:
Eli Lilly Japan
Article History
Received: 18 December 2023
Accepted: 1 February 2024
First Online: 24 February 2024
Declarations
:
: Kazuo Hara received lecture fees from Eli Lilly Japan K. K., Mitsubishi Tanabe Pharma Corporation, Nippon Boehringer Ingelheim Co. Ltd., AstraZeneca K.K. Ono Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Novo Nordisk, and Sumitomo Pharma Co. Ltd. Tetsuaki Hirase, Swathi Pathadka, Zhihong Cai, and Manaka Sato are full-time employees and stakeholders of Eli Lilly Japan. Noriyuki Ishida and Ryo Takemura have nothing to disclose.
: This study was conducted in accordance with the Declaration of Helsinki and Good Pharmacoepidemiology Practices. Per the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects [CitationRef removed], ethical review and informed consent were not required, as this was a non-interventional, retrospective study that used anonymized patient data.